Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: Evidence of improved vascular α1-adrenoreceptor signal transduction

American Heart Journal

Volumn 156, Issue 2, 2008, Pages 315-321

  Van Tassell, Benjamin W ^a   Rondina, Matthew T ^b   Huggins, Franklin ^a   Gilbert, Edward M ^b   Munger, Mark A ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; PHENYLEPHRINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG INFUSION; DRUG TOLERANCE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART RATE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MEAN ARTERIAL PRESSURE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARBAZOLES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PHENYLEPHRINE; PROPANOLAMINES; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION; SYSTOLE; VENTRICULAR DYSFUNCTION;

EID: 47649111642     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.04.004     Document Type: Article

References (39)

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353 (1999) 9-13
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
3. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
4. Yoshikawa T., Port J.D., Asano K., et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 17 Suppl B (1996) 8-16
5. Ruffolo Jr. R.R., Gellai M., Hieble J.P., et al. The pharmacology of carvedilol. Eur J Clin Pharmacol 38 Suppl 2 (1990) 82-88
6. Woodcock E.A. Roles of alpha1A- and alpha1B-adrenoceptors in heart: insights from studies of genetically modified mice. Clin Exp Pharmacol Physiol 34 (2007) 884-888
7. Packer M., Medina N., and Yushak M. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. J Am Coll Cardiol 7 (1986) 671-680
8. Sumner D.J., Elliott H.L., and Reid J.L. Analysis of the pressor dose response. Clin Pharmacol Ther 32 (1982) 450-458
9. Semplicini A., Pessina A.C., Rossi G.P., et al. Alpha-adrenoceptor blockade by labetalol during long-term dosing. Clin Pharmacol Ther 33 (1983) 278-282
10. Tham T.C., Guy S., McDermott B.J., et al. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol 40 (1995) 19-23
11. Dunnett C., and Goldsmith C. When and how to do multiple comparisons. In: Buncher C., and Tsay J. (Eds). Statistics in the pharmaceutical industry. 3rd ed. (2006), Chapman & Hall, New York 421-452
12. Ting N. Dose finding in drug development (2006), Springer
13. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
14. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26 (2005) 2259-2268
15. Hansson L., and Himmelmann A. Carvedilol in the treatment of hypertension-a review of the clinical data base. Scand Cardiovasc J Suppl 47 (1998) 67-80
16. Lund-Johansen P., Omvik P., Nordrehaug J.E., et al. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J Cardiovasc Pharmacol 19 Suppl 1 (1992) S27-S34
17. Krum H., Sackner-Bernstein J.D., Goldsmith R.L., et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92 (1995) 1499-1506
18. Metra M., Nardi M., Giubbini R., et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24 (1994) 1678-1687
19. Olsen S.L., Gilbert E.M., Renlund D.G., et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 25 (1995) 1225-1231
20. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
21. Giannattasio C., Cattaneo B.M., Seravalle G., et al. Alpha 1-blocking properties of carvedilol during acute and chronic administration. J Cardiovasc Pharmacol 19 Suppl 1 (1992) S18-S22
22. Kubo T., Azevedo E.R., Newton G.E., et al. Lack of evidence for peripheral alpha(1)-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 38 (2001) 1463-1469
23. Creager M.A., and Creager S.J. Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. J Am Coll Cardiol. 23 (1994) 401-405
24. Goldsmith S.R., Francis G.S., and Cohn J.N. Norepinephrine infusions in congestive heart failure. Am J Cardiol 56 (1985) 802-804
25. Graham R.M., Thornell I.R., Gain J.M., et al. Prazosin: the first-dose phenomenon. Br Med J 2 (1976) 1293-1294
26. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289 (2003) 712-718
27. Movsesian M.A., and Bristow M.R. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol 68 (2005) 25-48
28. Vatner D.E., Asai K., Iwase M., et al. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol 83 (1999) 80H-85H
29. Sigmund M., Jakob H., Becker H., et al. Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51 (1996) 127-132
30. Gilbert E.M., Olsen S.L., Renlund D.G., et al. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 71 (1993) 23C-29C
31. Kubo H., Margulies K.B., Piacentino III V., et al. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104 (2001) 1012-1018
32. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346 (2002) 1357-1365
33. Heilbrunn S.M., Shah P., Bristow M.R., et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79 (1989) 483-490
34. Bradley J.G., and Davis K.A. Orthostatic hypotension. Am Fam Physician 68 (2003) 2393-2398
35. Lipsitz L.A. Orthostatic hypotension in the elderly. N Engl J Med 321 (1989) 952-957
36. Ooi W.L., Barrett S., Hossain M., et al. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA 277 (1997) 1299-1304
37. Koshimizu T.A., Tsujimoto G., Hirasawa A., et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res 63 (2004) 662-672
38. Yang M., Ruan J., Voller M., et al. Differential regulation of human alpha1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 439-446
39. Lei B., Zhang Y., and Han C. Sustained norepinephrine stimulation induces different regulation of expression in three alpha1-adrenoceptor subtypes. Life Sci 69 (2001) 301-308